Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17175
Title: Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC).
Austin Authors: Chia, Puey Ling ;John, Thomas 
Affiliation: School of Cancer Medicine, La Trobe University, Victoria, Australia
Department of Medical Oncology, Olivia Newton-John Cancer and Wellness Centre, Heidelberg, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Issue Date: Jun-2016
Publication information: Journal of immunotherapy 2016; 39(5): 202-204
Abstract: Immunomodulatory agents that target PD-1 and its ligand (PD-L1) are being increasingly used in the management of lung cancer. Potential immune-related adverse events include dermatological complications which mostly are of low grade severity. The use of immune checkpoint inhibitors may lead to the exacerbation of autoimmune conditions. We report a case of a documented psoriasis flare with anti-PD-1 treatment for lung cancer.
URI: http://ahro.austin.org.au/austinjspui/handle/1/17175
DOI: 10.1097/CJI.0000000000000121
PubMed URL: 27163740
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/27163740
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

6
checked on Dec 2, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.